A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

NCT03817463 · clinicaltrials.gov ↗

COMPLETED

Status

327624

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
DRUG: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor

Sponsor

Boehringer Ingelheim